



Review: Analytical Method For Determination of Mefenamic Acid in Pharmaceutical and Biological Sample

Miss.Asha Chopade*, Mr. Babu Annulwad

Shrimati Latatai Baburao Patil Institute of Pharmacy, Khandgaon bendri

Abstract: Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory and antipyretic action. It is used to relieve mild to moderate pains. Mefenamic acid exerts peripheral as well as central analgesic action. the analytical method for identification and quantitative determination of mefenamic acid in pharmaceutical and biological samples. The most commonly methods for the determination of mefenamic acid are chromatographic (HPLC), spectrophotometric, colorimetric, dissolution, various chromatographic methods (HPTLC). A simple method HPLC was developed and validated for mefenamic acid. this method is precise, accurate to analysis mefenamic acid in Pharmaceutical & Biological Sample.¹

Keywords: mefenamic acid, spectrophotometry, Dissolution, chromatography

INTRODUCTION

Mefenamic acid an analgesic, antipyretic and weaker anti-inflammatory drug. Mefenamic acid is a non-steroidal anti-inflammatory drug with analgesic and antipyretic properties. chemically it belongs to the anthranilic acid derivative class. Mefenamic acid inhibits the enzyme cyclo-oxygenase to exert its anti-inflammatory effect and inhibits the synthesis of prostaglandin to produce analgesic action. mefenamic acid both central and peripheral analgesic action and is a non selective Cox inhibitor, which inhibits both the Cox-1 enzyme and Cox-2 enzyme.

It is white to off white, crystalline powder that darkens on prolonged exposure to light. it melts at 227-232° c insoluble in water, sparingly soluble in chloroform and ether, soluble in 0.1 M NaoH. It is prescribed in the treatment of rheumatoid arthritis, osteoarthritis and other joint disorders.²

Mefenamic acid (MFA) N-(2,3-xylyl)anthranilic acid




Fig-1:-Chemical Structure of Mefenamic Acid³

Adverse effect: Skin rashes, dizziness and other CNS manifestations have occurred. Haemolytic anaemia is a rare. Gastrointestinal Symptoms are the most common adverse effects. Diarrhoea occurs in a large number of patients.

It is contraindicated in gastrointestinal inflammation or ulceration, impairment of renal function. Mefenamic acid prolongs induction of labour by hypertonic saline.⁴

Pharmacokinetics: Oral absorption is slow but almost complete. It is highly bound to plasma protein-displacement interaction can occur; partly metabolized and excreted in urine as well as bile. Plasma $t^{1/2}$ is 2-4 hours.

Uses: Mefenamic acid as analgesic in muscle, joint and soft tissue pain. It is quite effective in dysmenorrhoea and may be useful in some cases of rheumatoid, osteoarthritis. Also used in treatment of Headache, dental, postoperative and postpartum pain.

Dose: 250-500mg.⁵

Methods for the determination of mefenamic acid:

- Spectrophotometric
- Colorimetric
- Dissolution
- Chromatographic
- Various LC chromatographic method

Sectrophotometric Method:

λ_{\max}	Sample	Solvent	Accuracy	Precision	Reference
270nm-0 339.6nm-1 315nm-2	Mefenamic acid+Meloxicam	Methanol+0.1 M NaoH	98.45-0 97.47-1 99.55-2	4.17-0 1.53-1 3.7-2	(6)
285nm	Mefenamic acid	0.1 N NaoH	99.64	0.4839-0.47 76	(7)
285nm	Mefenamic acid+Ofloxacin	0.1 N NaoH	99.36	1.423	(8)
233nm-M 245nm-D	Mefenamic acid +Drotaverine Hcl	2.0 M Sodium Benzoate	100.09-M 100.22-D	0.966-M 0.672-D	(9)
588nm	Mefenamic acid	Distilled Water	99.36	1.37	(10)
520nm-Meth od A 362nm-Meth od B 602nm-Meth od C	Mefenamic acid	Acetone	99.25-Method A 100.04-Method B 99.29-Method C	0.56-Metho d A 1.103-Meth od 1.575-Meth od C	(11)
253nm-D 304nm-M	Drotaverine Hcl+Mefenamic acid	Phosphate Buffer PH-6.8	99.06-D 98.70-M	1.154-D 1.129-M	(12)
654nm	Mefenamic acid	0.1 N NaoH	98.7	<1.93	(13)

Colorimetric Method: Colorimetric assay of Mefenamic acid in Pharmaceutical dosage forms using a newly developed chromogenic derivatizing reagent. There agent, diazotized 4-amino-3,5-dinitrobenzoic acid (ADBA), is a dinitrophenylarene diazonium ion, which function via anaromatic ring derivatization technique base on diazo coupling reaction. Diazo coupling of Mefenamic acid with reagent produced Bathochromic Shift.¹⁴

Dissolution Method: Dissolution testing combined Drotaverine Hcl and Mefenamic acid Tablet formulation(Doverin M) was performed in a Paddle type USP Dissolution Appratus. In these Paddle Type appratus 900ml various buffer and Surfactant media are used at 50 rpm & $37 \pm 0.5^\circ\text{C}$ For 45 min. Aliquots of 5.0ml were withdrawn at 5min Interval up to 45 min and Replaced with an equal volume if fresh medium to maintain Sink condition.at the end of the test, The withdrawn Samples were filtered, diluted with Phosphate buffer PH 6.8 & quantified by the developed & validated Sectrophotometric derivative Method (n=3).The amount of dissolved drugs was computed from the respective calibration curves & Then plotted against time. The media in which highest drug release occurred for Doverin-M. This medium was chosen for in vitro Dissloution Studies in Drofem.¹⁵

Solid Dispersion of Mefenamic acid showed a marked enhancement in Dissolution Rate & Dissolution Efficiency. The order of increasing Dissolution rate was Observed with increase in Crosprovidone ratio. The 1:4 ratio Mefenamic acid-CP a 2.26 fold increase in the Dissolution rate of Mefenamic acid was observed with Mefenamic acid-CP(1:4) solid dispersion.The solid dispersion in combined carries gave much higher rates of dissolution than super disintegrants

alone. MACP-PVP solid dispersion gave a 3.47 fold increase in the dissolution rate of Mefenamic acid. Super disintegrants alone or in combination with PVP could be used to enhance the dissolution rate of poorly soluble drug Mefenamic acid.¹⁶

Chromatographic Method:

Wavelength	Sample	Chromatographic Column	Mobile Phase	Reference
Variable 280nm	Mefenamic acid	Agilent Zorbax Eclipse XDB-C ₁₈ (150mm x 4.6mm, id 3.5µm)	Acetonitrile & 2% Triethylamine (PH adjusted to 4.2 with Phosphoric acid) in a ratio of 60:40	(17)
PDA Detector at 256nm	Ethamsylate, Mefenamic acid	C ₁₈ (ODS) Sunfire, 250mm x 4.6mm, 5µm (particle size)	Methanol & Water in the ratio of 82:18 v/v	(18)
Uv 256nm	Dicyclomine, Mefenamic acid	Lichrocart c ₁₈ (250 x 4.60x5im)	50 m M KH ₂ po ₄ :Acetonitrile in ratio of 75:25	(19)
215nm	Mefenamic acid, Dicyclomine Hydrochloride	C ₈ Luna (150mm x 4.6mm id,5µm)	Acetonitrile:Monobasic potassium dihydrogen phosphate (60:40, v/v)	(20)
275nm	Mefenamic acid	Chromolith(RP-18 e, 100mm x 4.6mm, 5µm)	A:0.1% Formic acid in deionised water, B:100% Acetonitrile	(21)
Uv 220nm	Paracetamol, Acetyl salicylic acid, Mefenamic acid, Cetirizine dihydrochloride	Nucleodur 100 c ₁₈ (250 x 4.6mm id,5µm)	Disodium hydrogen phosphate buffer adjusted to PH 6.5 using diluted orthophosphoric acid & Acetonitrile (60:40v/v)	(22)
310nm	Tranexamic acid, Mefenamic acid	C ₁₈ (4.6mm x250mm,5µm)	Buffer & Acetonitrile in the ratio 30:70v/v	(23)
275nm	Paracetamol, Mefenamic acid	Inertsil ODS 3v c ₁₈ (250 x 4.6mm id,5µm)	Methanol:Buffer(0.02M KH ₂ PO ₄) (75:25), PH 7.1 adjusted with 0.1 N NaoH	(24)
278nm	Mefenamic acid, Diclofenac	Atlantis d c ₁₈	0.025 M dibasic potassium phosphate (PH 6.0, adjusted with orthophosphoric acid) & Acetonitrile (65:35v/v)	(25)

Uv 227nm	Captopril, Ibuprofen, Flurbiprofen, Diclofenac sodium, Mefenamic acid	Purospher star c_{18} ($5\mu\text{m}$, $25 \times 0.46\text{cm}$)	Methanol:Water (80:20v/v)	(26)
Uv 230nm	Drotaverine Hcl, Mefenamic acid	Thermo BDS Hypersil c_8 ($25.0\text{cm} \times 4.6\text{mm}$, $5\mu\text{m}$)	Acetonitrile & Ammonium acetate buffer (20m M, PH 3.5 ± 0.05 adjusted with 85% phosphoric acid) in a ratio of 55:45 (v/v)	(27)
254nm	Mefenamic acid	Grace, alltima c_{18} ($250 \times 4.6\text{mm}$)	Methanol:Ammonium acetate PH 6 (67:33v/v)	(28)

Various LC Chromatographic Method:

Method	wavelength	Sample	Stationary	Mobile Phase	Reference
TLC-Densitometry	320nm	Mefenamic acid	Silica gel 60 F 254 plates	Chloroform:Methanol (9.0:0.1v/v)	(29)
HPTLC	254nm	Mefenamic acid, Paracetamol, Dicyclomine Hcl	Aluminium plates precoated with silica gel 60 F254	Toluene:Acetone:Formic acid(10:9.8:0.2)	(30)
HPTLC	287nm	Mefenamic acid, Tranexamic acid	Aluminium plates precoated with silica gel 60 F254	Toluene:Methanol (8:2v/v) & Methanol:Glacial acetic acid (9:1v/v)	(31)
HPTLC	270nm	Mefenamic acid	Merk precoated silica gel 60 F254 (0.2mm thickness) on Aluminium sheets	Chloroform:Methanol:Ammonia in the ratio of 6:4:0.1v/v/v	(32)
HPTLC	254nm	Mefenamic acid	Aluminium 60 F254 plates, (20cm x 10cm) with 0.25mm thickness	Toluene:Acetone:Methanol:Ammonia (6.5:2.5:1:0.1v/v/v/v)	(33)

Conclusion: The presented review discusses about various analytical methods for the determination of Mefenamic acid in Pharmaceutical & Biological samples.

New trends & advance for the quantification of Mefenamic acid based on using High Pressure Liquid Chromatography which is generally available. HPLC is the high sensitive, specificity & Faster time. Also HPLC is the automated. HPLC is used for the quantitative & qualitative determination of Mefenamic acid in comparison with the other methods.

Reference:

- 1)Sadeghi HB.,Panahi HA., Kahabadi M., Moniri E., Preconcentration and Determination of Mefenamic acid in Pharmaceutical & Biological Fluid sample by polymer-grafted silica gel solid-phase Extraction Following High Performance Liquid Chromatography, Iranian Journal of Pharmaceutical Research,2015,14(3):765-773.
- 2)Turkie Al-Awadies NS., Kadhim Al-saeedi MK., Determination of Mefenamic acid Using a New Mode of Irradiation & Detection (Twin solar cells) Through Turbidity Measurement by CFIA, Iraqi Journal of Science, 2016,57(2b):1052-1070.
- 3)Inadian Pharmacopoeia,Government of Inadia Ministry of Health and Family Welfare,2010,2:1641-1642.
- 4)Barar F.S.K.,Essential of Pharmacotherapeutics,5th edn,S chand,2009:208.
- 5)Tripathi KD,Essential of Medical Pharmacology,6th edn,Japee,2010:193.
- 6)Pomykalski A.,Hopkala.,Comparison of Classic and Derivative Uv Spectrophotometric Method for Quantification of Meloxicam and Mefenamic acid in Pharmaceutical Preparation,Acta Poloniae Pharmaceutica-drug Research,2011,68(3):317-323.
- 7)Dumal BR.,Bhusari KP.,Gante MH.,Jain NS.,Spectrophotometric Analysis for the Determination of Mefenamic acid in Pharmaceutical Formulation, Indo American Journal of Pharmaceutical Research,2015,5(11):3643-3650.
- 8)Kumar AK.,Jamuna KM.,Sasikala M.,Nithya S.,Gowthami C.,Bojja A.,Application of Uv Spectrophotometric Method for Drug Interaction Studies of Mefenamic acid with Ofloxacin, International Journal of Research in Pharmaceutical and Nano Sciences,2012,1(2):274-280.
- 9)Sharma MC.,Simultaneous Estimation and Validation of Mefenamic acid and Drotaverine Hydrochloride in Tablet Dosage Form,World Applied Sciences Journal,2013,28(9):1181-1187.
- 10)Othman NS.,Awades LS.,Spectrophotometric Determination of Mefenamic acid via Oxidative Coupling Reaction with 4-aminoantipyrine in Presence of N-chlorosuccinimide,Pak.,J.,Anal.,Environ., Chem.,2008,9(2):64-68.
- 11)Alarfaj NA.,Altamimi SA.,Almarshady LZ.,Spectrophotometric Determination of Mefenamic acid in Pharmaceutical Preparations,Asian Journal of Chemistry,2009,21(1):217-226.
- 12)Anumolu PD.,Sunitha G.,Raju YV.,Satheshbabu PR.,Subrahmanyam CVS.,Simple and Specific Validated Derivative Spectrophotometric Method for Simultaneous Quantification of Drotaverine Hcl and Mefenamic acid Combination in Tablets, Analytical Chemistry an Indian Journal,2014,14(1):11-16.
- 13)Othman NS.,Awadis LS.,Spectrophotometric Determination of Mefenamic acid in Pharmaceutical Preparation via Arsenazo(3rd)-Cerium(3rd) Reaction,2009,20(1):8-21.
- 14)Idowu SO.,Tambo SC.,Adegoke AO.,Olaniyi AA.,Novel Colorimetric Assay of Mefenamic acid using 4-amino-3,5-dinitrobenzoic acid(ADBA),Tropical Journal of Pharmaceutical Research,2002,1(1):15-22.
- 15)Anumolu PD., Gurralla S.,Yeradesi VR.,Puvvadi SR.,Chavali SV.,Development of Dissolution Test Method for Drotaverine Hcl and Mefenamic acid Combination using Derivative Spectrophotometric,Tropical Journal of Pharmaceutical Research,2013,12(2):227-232.

- 16) Nagabhushanam MV., Rani AS., Dissolution Enhancement of Mefenamic acid using Solid Dispersion in Croplidone, International Journal of Pharmacy and Pharmaceutical Sciences, 2011, 3(1):16-19.
- 17) Uddin AH., Mohamad HJ., Al-aama M., Amiruddin N., High Performance Liquid Chromatographic Determination of Mefenamic acid in Human Plasma using Uv Vis-Detector, International Journal of Pharmacy and Pharmaceutical Sciences, 2014, 6(11):167-170.
- 18) Rote AR., Nerkar DC., Thakare SC., RP-HPLC Method Development and Validation for Simultaneous Estimation of Ethamslate and Mefenamic acid in Tablet Formulation, International Journal of Institutional Pharmacy and Life Sciences, 2014, 4(6):1-9.
- 19) Baokar S., Mulgund S., Ranpise N., Development and Validation of RP-HPLC Method for Simultaneous Determination of Dicyclomine and Mefenamic acid, Journal of Pharmaceutical Research, 2014, 13(1):16-19.
- 20) Prajapati D., Raj H., Simultaneous Estimation of Mefenamic acid and Dicyclomine Hcl by RP-HPLC Method, International Journal Pharma Bio Science, 2012, 3(3): (P)611-625.
- 21) Al-qaim FF., Abdullah MP., Othman MR., Khalik WM., Development and Validation of HPLC Analytical Assay Method for Mefenamic acid Tablet (ponstan), International Journal Chemistry Science, 2014, 12(1):62-72.
- 22) Hayaldar FH., Vairal DL., Simultaneous Determination of Paracetamol, Acetyl salicylic acid, Mefenamic acid and Cetirizine Dihydrochloride in the Pharmaceutical Dosage Form, E-Journal of Chemistry, 2010, 7(S1):S495-S503.
- 23) Srivali Y., Srividya A., Ajitha A., Rao UM., Simultaneous Method Development and Validation Tranexamic acid and Mefenamic acid in Its Tablet Dosage Form by RP-HPLC, International Journal of Innovative Pharmaceutical Sciences and Research, 2014, 2(9):2189-2198.
- 24) Badgujar MA., Managaonkar KV., Simultaneous Determination of Paracetamol and Mefenamic acid in Tablet Dosage Form by HPLC, Journal of Chemical and Pharmaceutical Research, 2011, 3(4):893-989.
- 25) Binhashim NH., Hammami MM., Validated Reverse Phase HPLC Assay for the Determination of Mefenamic acid in Human Plasma, European Journal of Pharmaceutical and Medical Research, 2016, 3(7):16-21.
- 26) Sultan N., Saeed AM., Naveed S., Simultaneous Quantitation of Captopril and NSAID'S in API, Dosage Formulations and Human Serum by RP-HPLC, Journal of the Chinese Chemical Society, 2010, 57(1):62-67.
- 27) Dahivelkar PP., Bari SB., Bhoir S., Bhagwat AM., High Performance Liquid Chromatographic Estimation of Drotaverine Hcl and Mefenamic acid in Human Plasma, Iranian Journal of Pharmaceutical Research, 2009, 8(3):209-215.
- 28) Oswal T., Bhosale S., Naik S., Development of Validated Analytical Method of Mefenamic acid in an Emulgel, International Journal of Pharma Sciences and Research, 2014, 5(6):232-237.
- 29) Putri WK., Rivai H., Armin F., Development and Validation of Thin Layer Chromatography-densitometry Method for Analysis of Mefenamic acid in Tablet, Journal of Chemical and Pharmaceutical Research, 2016, 8(1):565-570.
- 30) Patel TK., Meshram DB., Development and Validation of High Performance Thin Layer Chromatography for Estimation of Mefenamic acid and Paracetamol, Dicyclomine Hcl in Tablet Dosage Form, International Journal of Pharmaceutical Science and Drug Research, 2015, 7(4):361-364.
- 31) Reddy NK., Potwale SE., Gabhe SY., Mahadik KR., HPTLC Double Development and Validation of Mefenamic acid in Combined Tablet Dosage Form, Pelagia Research Library, 2013, 4(60):16-21.
- 32) Rathinam S., Lakshmi K., HPTLC Method for the Simultaneous Estimation of Camylofin Dihydrochloride and Mefenamic acid in Pharmaceutical Tablet, International Journal of Pharmacy and Pharmaceutical Science, 2014, 6(10):585-589.
- 33) Dhaneshwar SR., Jagtap VN., Development and Validation of HPTLC Method for Simultaneous Estimation of Mefenamic acid and Paracetamol in Combined Dosage Form, 2012, 5(80):4263-4265.